en

Sign up
Investments involve risks and are not suitable for all investors.

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Cytokinetics Inc
Search

Cytokinetics Inc

Closed

Sector Healthcare

54.16 -3.03

Strong Buy

Price update 6 Sept 2024, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

53.97

Max

54.82

Key metrics

By Trading Economics

Income

-7.7M

-143M

Sales

24M

25M

EPS

0.08

Profit margin

-570.761

Employees

423

EBITDA

-622K

-117M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+51.32 upside

Dividends

By Dow Jones

Next Earnings

31 Oct 2024

Market Stats

By TradingEconomics

Market Cap

-58M

5.9B

Previous open

57.19

Previous close

54.16

News Sentiment

By Acuity

50%

50%

324 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

53.16 / 55.02 Support & Resistance

Cytokinetics Inc Chart

Related News

5 Jun 2024, 15:26 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

DJ

Read

11 Jan 2024, 17:47 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal

DJ

Read

8 Jan 2024, 18:28 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal

DJ

Read

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

DJ

Read

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

DJ

Read

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

DJ

Read

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

DJ

Read

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

DJ

Read

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

DJ

Read

11 Jan 2024, 17:47 UTC

Top News
Acquisitions, Mergers, Takeovers

Novartis Pursuit of Cytokinetics Cools -- Update

DJ

Read

11 Jan 2024, 17:19 UTC

Top News
Acquisitions, Mergers, Takeovers

Novartis Pursuit of Cytokinetics Cools -- WSJ

DJ

Read

11 Jan 2024, 17:19 UTC

Acquisitions, Mergers, Takeovers

Swiss Drug Maker Had Been Expected to Clinch Deal for Heart-Drug Developer as Soon as This Week -- WSJ

DJ

Read

11 Jan 2024, 17:19 UTC

Acquisitions, Mergers, Takeovers

Novartis Pursuit of Cytokinetics Cools, Sources Say -- WSJ

DJ

Read

8 Jan 2024, 21:42 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout. -- IBD

DJ

Read

8 Jan 2024, 19:13 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal -- IBD

DJ

Read

8 Jan 2024, 18:25 UTC

Acquisitions, Mergers, Takeovers

Novartis, Cytokinetics Near Merger: Report -- MarketWatch

DJ

Read

8 Jan 2024, 18:14 UTC

Top News
Acquisitions, Mergers, Takeovers

Novartis in Advanced Talks to Buy Cytokinetics -- Update

DJ

Read

8 Jan 2024, 17:56 UTC

Top News
Acquisitions, Mergers, Takeovers

Novartis in Advanced Talks to Buy Cytokinetics -- WSJ

DJ

Read

8 Jan 2024, 17:56 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Reached as Soon as This Week, Sources Say -- WSJ

DJ

Read

8 Jan 2024, 17:56 UTC

Acquisitions, Mergers, Takeovers

Novartis in Advanced Talks to Buy Cytokinetics, Sources Say -- WSJ

DJ

Read

31 Oct 2023, 17:49 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Cytokinetics May Have Some Tire Kickers -- Market Talk

DJ

Read

Peer Comparison

Price change

Cytokinetics Inc Forecast

Price Target

By TipRanks

51.32% upside

12 Months Forecast

Average 81.85 USD  51.32%

High 107 USD

Low 60 USD

Based on 14 Wall Street analysts offering 12 month price targets forCytokinetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

11

Buy

3

Hold

0

Sell

Based on 14 analysts giving stock ratings to Cytokinetics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

53.16 / 55.02Support & Resistance

Short Term

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Bearish Evidence

Recent bearish events outweigh bullish events.

Long Term

Weak Bearish Evidence

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

324 / 365 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cytokinetics Inc

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Other stocks from the sector

LLY

Eli Lilly and Co.

902.74

↓-0.9%

UNH

UnitedHealth Group Inc

596.8

↑ +0.31%

NVO

Novo Nordisk A-S

131.05

↑ +0.18%

JNJ

Johnson and Johnson

164.37

↓-0.29%

ABBV

AbbVie Inc

193.18

↑ +0.34%